rachel_ABQ said:The liver data is among the strongest non-weight findings in the class.
All true, with one condition: that curve is for people who reached the dose on schedule. Anyone who slowed the ladder for tolerability is on a different, flatter curve, and comparing yourself with the published mean will make you feel like a non-responder when you are not.
Dr.MetabolicMD said:The mechanism that matters here is not stomach emptying, it is central.
That reframing is the part I needed. I will report back once I have actually tried it.
rachel_ABQ said:The liver data is among the strongest non-weight findings in the class.
Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. The trial means are being read too generously in this thread. STEP populations were selected, supported, and titrated by protocol, and the real-world curves are consistently a few points worse. That difference is not noise, it is what happens when you remove the study infrastructure.
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsOne concrete data point for the thread. With resmetirom now available for MASH, combination approaches are being explored, so the standard of care in this area is moving faster than most threads assume.
Correct me if the detail matters more than I have assumed.
Moderator note: a post naming a supplier has been edited. Discuss suppliers in the review sections, not here. Thread quality here is what the rules are for. Keep it up.